Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Juliann Chmielecki; Tony Mok; Yi-Long Wu; Ji-Youn Han; Myung-Ju Ahn; Suresh S. Ramalingam; Thomas John; Isamu Okamoto; James Chih-Hsin Yang; Frances A. Shepherd; Krishna C. Bulusu; Gianluca Laus; Barbara Collins; J. Carl Barrett; Ryan J. Hartmaier; Vassiliki Papadimitrakopoulou

doi:10.1038/s41467-023-35962-x

Nature Communications (Feb 2023)

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Juliann Chmielecki,
Tony Mok,
Yi-Long Wu,
Ji-Youn Han,
Myung-Ju Ahn,
Suresh S. Ramalingam,
Thomas John,
Isamu Okamoto,
James Chih-Hsin Yang,
Frances A. Shepherd,
Krishna C. Bulusu,
Gianluca Laus,
Barbara Collins,
J. Carl Barrett,
Ryan J. Hartmaier,
Vassiliki Papadimitrakopoulou

Affiliations

Juliann Chmielecki: Translational Medicine, Oncology R&D, AstraZeneca
Tony Mok: State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong
Yi-Long Wu: Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences
Ji-Youn Han: Center for Lung Cancer, National Cancer Center
Myung-Ju Ahn: Section of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
Suresh S. Ramalingam: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine
Thomas John: Medical Oncology, Olivia Newton-John Cancer Research Institute, Austin Health
Isamu Okamoto: Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University
James Chih-Hsin Yang: Department of Medical Oncology, National Taiwan University Cancer Center
Frances A. Shepherd: Departments of Medical Oncology and Hematology, Princess Margaret Cancer Centre, and the University of Toronto
Krishna C. Bulusu: Translational Medicine, Oncology R&D, AstraZeneca
Gianluca Laus: Translational Medicine, Oncology R&D, AstraZeneca
Barbara Collins: Biometrics and Information Sciences, AstraZeneca
J. Carl Barrett: Translational Medicine, Oncology R&D, AstraZeneca
Ryan J. Hartmaier: Translational Medicine, Oncology R&D, AstraZeneca
Vassiliki Papadimitrakopoulou: Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center

DOI: https://doi.org/10.1038/s41467-023-35962-x
Journal volume & issue: Vol. 14, no. 1
pp. 1 – 8

Abstract

Read online

In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCLC. Here, by next-generation sequencing of circulating tumor DNA, the authors assess candidate mechanisms of acquired resistance to osimertinib in patients from the AURA3 trial.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal